Sir Pant Immunotherapeutics Appoints Jelle Kijlstra, Md, Mba As Chief Medical Officer
07/11/23, 1:30 PM
Location
hummelstownIndustry
biotechnology
Position
chief medical officer
SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Jelle Kijlstra, MD, MBA as its new Chief Medical Officer. Dr. Kijlstra brings more than 30 years of experience as a clinician-scientist and drug developer to SIRPant Immunotherapeutics where he will be responsible for advancing the development of SIRPant-M™ an autologous SIRPαlow macrophage-based product, including the ongoing Phase 1 clinical study of SI-101 in Relapsed/Refractory Non-Hodgkins Lymphomas and the filing of a solid tumor-focused IND later this year.
Company Info
Location
1214 research boulevard, suite 2010
hummelstown, pennsylvania, united states
Additional Info
BobcatBio, Inc. was formerly known as SIRPant Immunotherapeutics Inc. BobcatBio is spearheading the development of macrophage-based cell therapies for the treatment of solid tumors. Leveraging our deep understanding of the biology of myeloid cells—the cells that drive immune responses—BobcatBio engineers specially-equipped macrophages from a patient’s own blood cells without any genetic modifications and then provides those cells back to the patient.